Stemgent
The development and commercialization of therapeutics and cellular technologies derived from the placenta.
Launch date
Employees
Market cap
-
Enterprise valuation
$45—68m (Dealroom.co estimates Aug 2012.)
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$6.5m | Series A | ||
$14.0m | Series B | ||
$2.7m | Debt | ||
| N/A | $5.6m | Early VC | |
| N/A | $750k | Debt | |
$10.6m | Series B | ||
| N/A | $580k | Debt | |
| N/A | $6.3m | Early VC | |
| N/A | $11.3m | Late VC | |
| N/A | N/A | IPO | |
| Total Funding | $54.3m | ||
Recent News about Stemgent
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.